Although provider-level volume is frequently associated with outcomes in cancers requiring complex surgeries, whether similar relations exist for cancers treated primarily with systemic therapy is unknown. METHODS: Using a population-based cohort analysis of older adults diagnosed with diffuse large B cell lymphoma (DLBCL) during the years 2004-2011, we evaluated the association between oncologist volume and 4 clinical outcomes (receipt of any chemotherapy, receipt of an anthracycline-containing or equivalent regimen, early hospitalization, and overall survival). Our primary explanatory variable was lymphoma treatment volume, defined as the number of patients with newly diagnosed lymphoma for which an oncologist initiated therapy during a 12-month look-back period from each incident DLBCL case. RESULTS: We identified 8247 Medicare beneficiaries who were newly diagnosed with DLBCL. Chemotherapy was administered to 6202 (75.2%) beneficiaries, and 71.4% of cytotoxic regimens contained an anthracycline. Beneficiaries who were treated by higher-volume oncologists had increased odds of receiving chemotherapy (adjusted odds ratio [aOR], 1.45; 95% confidence interval [CI], 1.24-1.70; P <.001) and of receiving an anthracycline-containing regimen (aOR, 1.26; 95% CI, 1.06-1.50; P = .009). Receiving care from a higher-volume provider was also associated with decreased hospitalization (aOR, 0.80; 95% CI, 0.69-0.95; P = .007) and improved survival (adjusted hazard ratio, 0.85; 95% CI, 0.79-0.92; P < .001). CONCLUSION: In older adults diagnosed with DLBCL, receiving care from a provider with more experience treating lymphoma patients was associated with receipt of guideline-adherent therapy, reduced hospitalizations, and improved survival. Clinical volume may be an important factor in providing high-quality cancer care in the modern era. Cancer 2018;124:4211-4220.
INTRODUCTION
For cancer patients undergoing complex procedures, hospital and surgeon-level case volume is frequently associated with important clinical outcomes. [1] [2] [3] In recognition of increasing complexity within medical oncology, recent observational studies have measured the association of facility-level volume with survival in select malignancies. [4] [5] [6] [7] However, little is known about the relationship between oncologist experience and nonsurgical cancer outcomes. 8, 9 Diffuse large B cell lymphoma (DLBCL) in older adults represents an excellent clinical setting for studying the relationship between oncologist volume and cancer outcomes. DLBCL is the most common subtype of non-Hodgkin lymphoma (NHL) and has a median age at diagnosis of 70 years. 10 Notably, NHL is one of the 10 leading causes of cancer death in the United States and is one of the few major cancers for which surgery is not one of the primary treatment modalities. Hence, previous studies of provider volume, which largely focus on surgery, have tended to overlook NHL. Yet treatment of NHL-and specifically DLBCL-is increasingly complex. On the one hand, older adults with DLBCL may be cured with immunochemotherapy, 11, 12 and guidelines generally recommend rituximab combined with an anthracycline-containing or anthracycline-equivalent regimen regardless of age. 13, 14 However, comorbidities and concerns regarding treatment toxicity can limit the administration of chemotherapy, [15] [16] [17] [18] [19] with more than one quarter of older adults with DLBCL in the United States not receiving any cytotoxic chemotherapy. 20 Whether oncologist experience with treating older lymphoma patients is associated with therapy selection and clinical outcomes in this at-risk population is unknown.
To evaluate the association of oncologist volume and high-quality cancer care, we conducted a population-based cohort analysis of older adults with DLBCL. We hypothesized that patients evaluated by oncologists who have more experience treating older adults with NHL would be more likely to receive an anthracycline-containing or equivalent regimen and have a lower incidence of hospitalizations. We also postulated that older adults with DLBCL would have better survival if they were under the care of oncologists who had more experience treating patients with lymphoma.
METHODS

Data source
We used the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data set. SEER-Medicare includes demographic, cancer characteristics and survival data from population-based cancer registries linked to Medicare enrollment and claims data. 21, 22 The Yale Human Investigation Committee determined that this study did not directly involve human subjects.
Study Sample
We identified Medicare beneficiaries aged 66 years or older who had been diagnosed with DLBCL between 2004 and 2011. We included individuals who 1) had known month of lymphoma diagnosis, not reported on death certificate or autopsy only; 2) were diagnosed with DLBCL as the first primary malignancy in SEER; 3) had continuous Medicare Parts A and B and no Medicare Advantage coverage during the study period; 4) had not received chemotherapy in the year prior to diagnosis; and 5) did not have another malignancy diagnosed within 12 months of DLBCL diagnosis.
For each beneficiary who received parenteral therapy following their DLBCL diagnosis, claims from the first date of treatment (index date) were used to assign the primary medical oncologist (Supporting Table 1 ). For beneficiaries diagnosed with DLBCL who did not receive any lymphoma-directed therapy, we assigned the primary medical oncologist based on the claims closest to the diagnosis date (index date) associated with either 1) a physician specialty code for hematology and/or oncology or 2) a physician previously identified as initiating parenteral therapy for a DLBCL patient in our study cohort. We excluded individuals for whom we were unable to assign a primary oncologist (Fig. 1 ).
Measures
B cell NHL treatment volume
Our main explanatory variable was the number of systemic treatment initiations assigned to the primary oncologist for each incident DLBCL case during a 12-month lookback period from each patient's index date (Supporting Fig. 1 ). For our primary analysis, we included treatment initiations among B cell lymphoma subtypes because management strategies can overlap across histologies. 14 Therefore, clinical experience garnered by treating older adults with other B cell NHL types may be applicable to the care of beneficiaries diagnosed with DLBCL.
To create our cohort for volume measurement, we first identified beneficiaries age 66 years or older diagnosed with any B cell NHL during the years 2004-2011 using the International Classification of Diseases for Oncology (3rd Edition) histology codes. We used Healthcare Common Procedure Coding System codes to identify claims for lymphoma-directed parenteral therapy following diagnosis (Supporting Table 1 ). Claims on the date of first-line treatment initiation were used to match the treating oncologist to beneficiaries within our B cell NHL cohort.
For each beneficiary in our DLBCL study cohort, we calculated the number of B cell NHL patients for whom an oncologist initiated parenteral therapy within the 12 months before their DLBCL diagnosis (untreated patients) or treatment initiation date (treated patients). Due to the required 12-month look-back period, we excluded beneficiaries with DLBCL initiating therapy before January 1, 2005. We categorized oncologist lymphoma volume as 0, 1-2, or ≥3 individuals initiated in the preceding 12 months. Our high-volume category Cancer November 1, 2018 (≥3 treatment initiations in the previous year) corresponded to the upper tertile, a cutoff previously used to define high physician volume in surgical settings. 23, 24 Outcome measures
We assessed the quality of DLBCL care by evaluating 1) receipt of any cytotoxic chemotherapy, 2) receipt of an anthracycline-containing or equivalent regimen, 3) hospitalization following treatment initiation, and 4) overall survival from DLBCL diagnosis. We required beneficiaries to have 1 or more claims for a cytotoxic chemotherapy after their DLBCL diagnosis to be classified as receiving chemotherapy (Supporting Table 1 ). Rituximab monotherapy was not classified as chemotherapy receipt. Cytotoxic therapy was further classified as anthracycline-containing or anthracycline-equivalent (cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or CHOP-like) if 1 or more claims for an anthracycline, etoposide, and/or mitoxantrone regimen occurred within 14 days of the first claim for a cytotoxic chemotherapy. 14, 18 We next evaluated whether DLBCL beneficiaries experienced hospitalization after treatment initiation. Here, we identified any inpatient hospital claim in the 30 days following the initiation of cytotoxic chemotherapy. 18 Lastly, survival was calculated from date of DLBCL diagnosis until death. Patients were censored if they did not have death recorded by the date of the last available follow-up (December 31, 2013).
Covariates
For each beneficiary, we identified age at diagnosis, sex, race, marital status, year of diagnosis, geographic region, metro status of residence, and Medicaid dual enrollment in the year before SEER diagnosis. We also included median household income at the census tract level as a proxy for socioeconomic status. Clinical characteristics including Ann Arbor staging, B symptoms, and primary site were derived from SEER. We used claims data to measure baseline health status at time of DLBCL diagnosis, including the Elixhauser comorbidity burden and a claims-based disability indicator. 25, 26 In addition to baseline patient characteristics, we used Medicare claims to assess delivery of radiation therapy, use of prophylactic growth factor, and treatment setting. We classified growth factor (granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor) as being primary prophylactic if claims were present within 5 days of initiating cytotoxic chemotherapy. 27, 28 We characterized treatment setting as outpatient hospital-based or physician office-based using the location of Medicare claims from the index date. 29 
Statistical Analysis
Bivariate comparisons between the distributions of patient characteristics and oncologist volume were evaluated using chi-square tests. We estimated 3 separate hierarchical multivariable logistic regression models adjusting for beneficiary-level covariates and nesting within physicians: 1) receipt of any chemotherapy, 2) receipt of an anthracycline-containing or anthracycline-equivalent (CHOP/CHOP-like) regimen, and 3) hospitalization within 30 days of initiation. We used Kaplan-Meier survival curves and Cox proportional hazards regression to assess the association between oncologist volume and overall survival. We found no significant violation of the proportional hazards assumption using the cumulative sum of Martingale residuals and the Kolmogorov-type supremum test. 30 In addition to our primary analysis using B cell NHL volume, we performed a sensitivity analysis restricting our volume measure to DLBCL-specific treatment initiations. We categorized our DLBCL-specific volume using the same grouping of 0, 1-2, or ≥3 treatment initiations during the previous 12 months. All statistical analyses were completed using SAS version 9.4 (SAS Institute Inc., Cary, NC) with 2-sided statistical tests and α = 0.05.
RESULTS
We identified 8247 Medicare beneficiaries newly diagnosed with DLBCL (Fig. 1) . The median age was 77 years (interquartile range [IQR], 72-83). These beneficiaries received their primary lymphoma care from 2518 oncologists, who initiated rituximab and/or chemotherapy on a total of 25,122 Medicare beneficiaries diagnosed with B cell NHL between 2004 and 2011. The median number of treatment initiations for B cell NHL in the 12 months preceding each beneficiary with newly diagnosed DLBCL was 2 (range, 0-30; IQR 1-3). Patients initiating cytotoxic chemotherapy with high-volume oncologists (≥3 initiations per 12 months) were more likely to be white, reside in the Midwest or South, live in a nonmetropolitan area, not be disabled, and receive treatment in a physician office setting (Table 1) .
Cytotoxic Chemotherapy
The majority of beneficiaries diagnosed with DLBCL received cytotoxic chemotherapy (n = 6202; 75.2%). We observed a significant dose-dependent relationship Table 2) . Among patients receiving cytotoxic chemotherapy, 4429 (71.4%) received an anthracycline-containing or anthracycline-equivalent regimen (CHOP/ CHOP-like). Patients who received care from an oncologist with 1-2 treatment initiations were significantly more likely to have received CHOP/CHOP-like treatment compared with patients who received care from an oncologist with no treatment initiations (aOR, 1.38; 95% CI, 1.17-1.63; P < .001). A similar association was seen in patients who were treated by a high-volume oncologist, with 26% increased odds of receiving CHOP/ CHOP-like treatment compared with patients who were treated by an oncologist with no initiations (aOR, 1.26; 95% CI, 1.06-1.50; P = .009).
In addition to our primary exposure variable of oncologist volume, several patient-level characteristics were associated with receipt of any cytotoxic chemotherapy and receipt of CHOP/CHOP-like treatment. Significant characteristics in both models included age, stage, census income, comorbidity score, Medicaid dual coverage, disability status, and treatment setting (Supporting Table 2 ).
Hospitalization
Among patients who received cytotoxic chemotherapy, 1596 (25.7%) experienced 1 or more hospitalization within 30 days of treatment initiation. Hospitalization rates were similar among patients who were treated by oncologists with an intermediate or low volume of treatments (26.8% vs 27.6% [P = .57]; aOR, 0.98; 95% CI, 0.84-1.14; P = .82). However, patients treated by highvolume oncologists had lower hospitalization rates (23.5%) compared with either intermediate-volume (P = .010) or low-volume (P = .005) providers, with 20% lower odds of hospitalization compared with patients who were treated by oncologists with the lowest volume of lymphoma treatments (aOR, 0.80; 95% CI, 0.69-0.94; P < .001) ( Table 2) .
Survival
The median follow-up time for our DLBCL cohort was 28 months (IQR, 5-57 months) and 59.5% of patients died before the end of our study. We identified significant variation in overall survival by oncologist volume of treatment initiations for the full cohort (P < .001 [log-rank]; Fig. 2 ). After comprehensive adjustment for beneficiarylevel covariates, intermediate volume was associated with 8% reduced risk of death (adjusted hazard ratio [aHR], 0.92; 95% CI, 0.85-0.99; P = .019), and high volume was associated with 15% reduced risk of death (aHR, 0.85; 95% CI, 0.79-0.92; P < .001) compared with low volume. In contrast, no significant survival differences by oncologist volume were observed among the group of patients receiving cytotoxic chemotherapy or the subgroup receiving CHOP/CHOP-like treatment (Fig. 2) . Among treated patients, 158 (2.6%) patients died within 30 days of initiating cytotoxic chemotherapy, and this percentage was similar across oncologist volume.
Sensitivity Analysis
Our sensitivity analysis considered DLBCL-specific treatment volume. The median number of beneficiaries with DLBCL that a provider initiated during the previous year was 1 (range, 0-18; IQR, 0-3). Findings were similar to our primary analysis, with beneficiaries receiving care under oncologists with higher DLBCL-specific volume having increased odds of receiving chemotherapy and lower odds of hospitalization (Supporting Table 3 ). However, the DLBCL-specific volume measure remained independently associated with survival across additional subgroups, including those receiving cytotoxic chemotherapy (Supporting Table 4 ).
DISCUSSION
In our population-based cohort study, oncologist experience treating older patients with lymphoma was associated with important clinical outcomes in Medicare beneficiaries newly diagnosed with DLBCL. Specifically, beneficiaries receiving care from oncologists with the least number of prior lymphoma treatments had lower odds of receiving guideline-adherent chemotherapy, higher hospitalization rates, and worse survival. Despite the fact that NHL is the most common group of hematologic malignancies, 31 many oncologists infrequently treated Medicare beneficiaries with NHL in our population-based cohort study. In fact, nearly 1 in 4 Medicare beneficiaries diagnosed with DLBCL were under the care of an oncologist who had not initiated NHL therapy on another Medicare beneficiary during the previous 12 months. Our study adds to the literature by opening an important new dimension to the volume-outcome relationship. To our knowledge, this is the first population-based study evaluating the association between oncologist volume and outcomes in a cancer treated primarily with systemic chemotherapy. Volume-outcome analyses evaluating nonsurgical cancer care are scarce and have primarily focused on hospital-level case volume and overall survival for select malignancies, [4] [5] [6] [7] including NHL. 4 Our analysis has several important strengths. First, we had access to both rich clinical data through SEER and comprehensive treatment data using Medicare claims. This contrasts with previous analyses evaluating facility-level volume-outcome relationships in cancer, where treatment details were limited. [4] [5] [6] [7] 32 Comprehensive Medicare claims allowed us to evaluate the association of oncologist experience with important clinical outcomes, including therapy selection and posttreatment hospitalizations. Similarly, we were able to explore the association of volume and survival depending on whether chemotherapy was received. We found oncologist NHL volume was associated with survival when considering the entire DLBCL cohort, but not independently associated when analyzing the subgroup receiving guideline-recommended therapy. This novel finding suggests that provider experience with treating older adults with lymphoma may influence the propensity of chemotherapy recommendations for patients newly diagnosed with DLBCL, a potentially curable malignancy even in older adults with significant comorbidities. 11, 12, 15, 33 Use of cancer registry data linked to comprehensive Medicare claims also allowed a dynamic approach to measuring provider volume. Here, we used a rolling 12-month look-back period to measure the number of B cell NHL patients an oncologist initiated on therapy before rendering care for a Medicare beneficiary newly diagnosed with DLBCL. The majority of volume-outcome studies categorize volume using 1 time period. 24 This static measure offers average case volume; our 12-month retrospect approach is more precise and accommodates clinical practice changes at the provider level over time.
Although our study has a number of important findings, there are several limitations to consider. First, our volume measure was restricted to the Medicare feefor-service population and should be viewed as a relative rather than absolute measure of treatment volume. Although Medicare is the largest purchaser of cancer care in the United States and more than half of NHL patients are aged >65 years, 10 oncologists in our study likely initiated NHL treatment in younger individuals or beneficiaries with Medicare-managed care plans not captured in our data. Therefore, absolute NHL treatment volume at the oncologist level is underreported in our study. Prior studies have utilized SEER-Medicare to define surgeon-level volume and revealed strong associations with clinical outcomes. 34, 35 Furthermore, we categorized our volume measure into tertiles based on previous volumeoutcome studies, 23, 24 but other stratifications have been used. 34, 35 We explored whether outcomes in our high-volume group were strongly influenced by providers in the ≥90th percentile and did not find significant differences within this group (ie, outcomes were similar for patients treated by providers with 3-5 initiations compared with ≥6 initiations).
Second, our analysis considers oncologist volume without accommodating for variation in facility-level case volume. In the setting of complex procedures, immediate post-procedural outcomes may be associated with both provider and facility-level case volume. 36, 37 However, treatment decisions in the setting of newly diagnosed DLBCL are much more likely to be driven by provider rather than facility-level factors. Our population-based cohort analysis uses Medicare claims and may not be generalizable to younger DLBCL patients, those receiving care outside of fee-for-service coverage, or individuals diagnosed with other lymphoma subtypes. However, DLBCL has the highest incidence among all hematologic malignancies and increases with age, 10 allowing our findings to be relevant to a sizable portion of patients diagnosed with hematologic malignancies in the United States. Furthermore, SEER-Medicare allowed us to include several important clinical parameters (ie, lymphoma stage and comorbidities) in our models, but residual confounding from unmeasured variables (ie, travel distance to provider, revised International Prognostic Index) 38 could still influence our findings. Lastly, we recognize that cytotoxic chemotherapy, whether CHOP/ CHOP-like or other, may not be feasible or aligned with patient preferences in our entire cohort of older adults. However, our analysis adjusted for comprehensive patient-level characteristics and found lymphoma volume to be associated with reduced hospitalizations, in addition to treatment selection and survival.
Recent advances have increased the complexity of providing high-quality cancer care. Research outside the field of medical oncology suggests clinical volume may be an important factor behind optimal delivery of specialized healthcare. We found oncologist experience with lymphoma treatment associated with survival in older adults newly diagnosed with DLBCL. Furthermore, lower oncologist volume was associated with reduced odds of receiving cytotoxic chemotherapy, and this treatment selection likely contributed to the observed volume-survival association. Should future studies identify consistent volume-outcome relations in the increasingly complex field of medical oncology, care delivery and system-based interventions may be warranted.
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